STOCKHOLM, SWEDEN – July 23, 2025. Gesynta Pharma AB on July 22 announced it has raised an additional SEK 43 million in its Series B second closing, bringing the total Series B capital to SEK 347 million. New prominent investors, HealthCap and Hadean Growth Fund, joined the round, led by Innovestor Life Science. These additional funds will facilitate the preparation of the future Phase 3 program of vipoglanstat, a drug candidate aimed at revolutionizing the treatment of endometriosis, a disease affecting 190 million women globally. In conjunction with this capital infusion, Gesynta Pharma strengthens its board with the appointment of three new directors: Kristina Ekberg, partner at HealthCap, and independent directors Cristina Csimma and David Colpman.
Gesynta Pharma is preparing a Phase 2 clinical trial for vipoglanstat, a novel non-hormonal, non-opioid treatment for endometriosis. This chronic inflammatory disease, affecting one in ten women of reproductive age, can cause intense pain, impaired quality of life and infertility. Vipoglanstat targets mPGES-1, an enzyme found in endometriotic lesions (tissue similar to the lining of the uterus, growing outside the uterus), with preclinical data demonstrating marked reductions in both pain and lesions. The upcoming clinical proof-of-concept study will include approximately 190 patients in several countries across Europe.
“It is with great enthusiasm that we join this robust investor syndicate, dedicated to addressing a significant unmet medical need,” commented HealthCap partner Kristina Ekberg. “This investment reflects our strong confidence in Gesynta Pharma’s vision and its potential to deliver a genuine breakthrough in women’s health.”
Pekka Simula, Partner at Innovestor Life Science notes: ”HealthCap’s participation is a tremendous addition to our Series B round. Their solid experience in the life science sector significantly enhances our syndicate, providing robust support for our ambitious goals.”
“This Series B second closing, reinforced by the commitment of new investors HealthCap and Hadean Growth Fund, accelerates our mission to deliver vipoglanstat as an innovative, non-hormonal solution for endometriosis patients,” remarks Roger Franklin, Chairman of Gesynta Pharma and partner at Hadean Ventures. “Furthermore, we are immensely pleased to welcome Cristina, David and Kristina to our board of directors. Their extensive expertise in drug development, business development, and venture capital will be instrumental in supporting our strategic growth, accelerating our efforts to deliver better treatments and enhance patient’s quality of life.”